Business Wire
24 Dec 2025, 14:00 UTC · 46w ago
FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
Impact · against what's priced in
OMER receives a significant value inflection point with the first-ever FDA approval for a lectin pathway inhibitor in TA-TMA. This enables immediate commercialization and revenue generation in a market with no direct mechanism-of-action competitors.
- OMER+0.90
No priced-in read yet
- In context
The FDA approval of YARTEMLEA for TA-TMA transforms the company from a clinical-stage entity to a commercial-stage one with a first-mover advantage in lectin pathway inhibition.
Read from the article alone
Top 1 mover · tap to explore
